08.06.2022 • NewsKBRRecycling

KBR Invests in Plastics Recycling Firm

US science, technology and engineering group KBR is investing a further $100 million in chemical recycling firm Mura Technology. The move takes KBR’s aggregate investment in Mura to 18.5%.

The funds will be paid in two tranches – the first in the quarter ending Jun. 30 and the rest in 2023. Alongside the investment, a representative from KBR management will join Mura’s board of directors to help shape the business’s future strategy.

KBR entered into an alliance in January 2021 to become Mura’s exclusive licensor for its Hydrothermal-Plastic Recycling Technology, Hydro-PRT. Together, the companies have won numerous license awards and feasibility studies, saying the alliance has also produced advances in process technology innovation, such as closed loop power, water recycling, modularization and digital operating solutions. KBR may also expand its engagement on Mura’s own projects to provide advanced engineering, program management and integration expertise.

“The combination of Mura’s game-changing Hydro-PRT technology with KBR’s scalable engineering and licensing expertise has now established a world-leading alliance in the advanced recycling of plastics," said Mura CEO Steve Mahon.

KBR president and CEO Stuart Bradie added: “With a strategic approach to commercializing and scaling its proprietary, differentiated plastics recycling solution, Mura is very well positioned for profitable growth and value creation as the plastics circular economy develops and matures.”

The monies will provide Mura with further capital to accelerate development of its plastics recycling projects. The company announced a licensing agreement with Japan’s Mitsubishi Chemical in June 2021, and has also formed strategic partnerships with Dow and Chevron Phillips Chemical.

Together, Mura and its licensees plan to build facilities around the world – the first is due to open in Teesside, UK, at the end of 2022, followed by sites in Germany and the US, where construction is due to start in the coming months. Further sites are planned for Europe and Asia, including a project with LG Chem in South Korea. Mura’s target is to reach 1 million t/y of recycling capacity in operation or development by 2025.

Author: Elaine Burridge, Freelance Journalist

Photo by Sigmund on Unsplash
Photo by Sigmund on Unsplash

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.